The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...

Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Cancer drugs' sexual toxicity warrants a "call to action" among oncologists to address the problem. ( Lancet Oncology) U.S.

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as first-line treatment for adults with unresectable or metastatic HCC.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...